Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Public ClinicalTrials.gov record NCT01536054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best dose and schedule of sirolimus when given together with vaccine therapy in treating patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with sirolimus may be an effective treatment for ovarian, fallopian tube, or primary peritoneal cancer
Study identification
- NCT ID
- NCT01536054
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 7 participants
Conditions and interventions
Conditions
- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Primary Peritoneal Cavity Cancer
- Stage IIA Fallopian Tube Cancer
- Stage IIA Ovarian Epithelial Cancer
- Stage IIA Primary Peritoneal Cavity Cancer
- Stage IIB Fallopian Tube Cancer
- Stage IIB Ovarian Epithelial Cancer
- Stage IIB Primary Peritoneal Cavity Cancer
- Stage IIC Fallopian Tube Cancer
- Stage IIC Ovarian Epithelial Cancer
- Stage IIC Primary Peritoneal Cavity Cancer
- Stage IIIA Fallopian Tube Cancer
- Stage IIIA Ovarian Epithelial Cancer
- Stage IIIA Primary Peritoneal Cavity Cancer
- Stage IIIB Fallopian Tube Cancer
- Stage IIIB Ovarian Epithelial Cancer
- Stage IIIB Primary Peritoneal Cavity Cancer
- Stage IIIC Fallopian Tube Cancer
- Stage IIIC Ovarian Epithelial Cancer
- Stage IIIC Primary Peritoneal Cavity Cancer
- Stage IV Fallopian Tube Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Primary Peritoneal Cavity Cancer
Interventions
- ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine Biological
- sirolimus Drug
- laboratory biomarker analysis Other
- sargramostim Biological
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 19, 2012
- Primary completion
- Apr 20, 2015
- Completion
- Apr 20, 2015
- Last update posted
- Mar 26, 2020
2012 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01536054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2020 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01536054 live on ClinicalTrials.gov.